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Nitric oxide (NO) plays a crucial role not only in regulation of 
blood pressure but also in maintenance of cardiac autonomic 
tone and its deficiency induced hypertension is accompanied by 
cardiac autonomic dysfunction. However, underlying mechanisms 
are not clearly defined. We hypothesized that sympathetic 
activation mediates hemodynamic and cardiac autonomic 
changes consequent to deficient NO synthesis. We used chemical 
sympathectomy by 6-hydroxydopamine to examine the influence 
of sympathetic innervation on baroreflex sensitivity (BRS) and 
heart rate variability (HRV) of chronic NG-nitro-L-arginine methyl 
ester (L-NAME) treated adult Wistar rats. BRS was determined 
from heart rate responses to changes in systolic arterial pressure 
achieved by intravenous administration of phenylephrine and 
sodium nitroprusside. Time and frequency domain measures of 
HRV were calculated from 5-min electrocardiogram recordings. 
Chronic L-NAME administration (50 mg/kg per day for 7 days 
orally through gavage) in control rats produced significant 
elevation of blood pressure, tachycardia, attenuation of BRS for 
bradycardia and tachycardia reflex and fall in time as well as 
frequency domain parameters of HRV. Sympathectomy 
completely abolished the pressor as well as tachycardic effect of 
chronic L-NAME. In addition, BRS and HRV improved after 
removal of sympathetic influence in chronic L-NAME treated rats. 
These results support the concept that an exaggerated 
sympathetic activity is the principal mechanism of chronic 
L-NAME hypertension and associated autonomic dysfunction. 
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Nitric oxide (NO) generated from L-arginine by 
the action of the enzyme nitric oxide synthase (NOS) plays 
an important role in basal and dynamic regulation of 
circulation (Gladwin et al. 2004). It has been firmly 
established that pharmacological inhibition of NO 
synthesis produces acute and chronic hypertension in many 
animal species (Rees et al. 1989, Aisaka et al. 1989), but 
the underlying mechanisms mediating the rise in pressure 
are incompletely understood. Although this pressor 
response at first was attributed solely to inhibition of 
tonically produced vasodilatory NO (Rees et al. 1989, 
Aisaka et al. 1989), an emerging body of literature 
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suggests the possible role of sympathetic nervous system 
(SNS), renin-angiotensin-aldosterone system and of the 
oxidative stress (Bernatova 2014), however the results are 
inconclusive. The existence of sympathoexcitatory state 
after NOS inhibition is quite possible as NO also 
modulates autonomic control of cardiovascular system by 
tonically inhibiting sympathetic outflow and increasing 
parasympathetic influence (Schultz 2009). However, the 
role of sympathetic neural control during pharmacological 
inhibition of NO by inhibitors such as L-NAME remains ill 
defined. Few studies reported enhanced sympathetic flow 
in L-NAME hypertension (Biancardi et al. 2007, Young et 
al. 2009, Chaswal et al. 2011, Augustyniak et al. 2006) 
whereas others showed no association between the two 
(dos Santos et al. 2010, Ramchandra et al. 2007). Although 
involvement of sympathetic innervation in L-NAME 
hypertensive model has been addressed in earlier studies 
but to the best of our knowledge, there is absence of a 
comprehensive study which has examined alterations in 
cardiac autonomic functions after L-NAME treatment and 
influence of sympathetic tone on this. If NO inhibition is 
characterized by sympathetic over activity then removal of 
sympathetic influence should restore cardiac autonomic 
alterations following L-NAME treatment. Therefore, in 
order to clarify the role of sympathetic innervation in 
hemodynamic and cardiac autonomic changes resulting 
after NO synthesis inhibition, we measured noninvasive 
markers of cardiac autonomic control such as baroreflex 
sensitivity and heart rate variability after chronic L-NAME 
treatment in rats with or without sympathectomy. 
 
Materials and Methods 
 
Animals 
Forty adult male Wistar rats weighing between 
250-300 g were used. Rats were housed in polyethylene 
cages with a controlled temperature (25±2 °C) and a 
12:12-h dark-light cycle. They were allowed food and 
water ad libitum. 
The experimental protocol was approved by 
Institutional Animal Ethical Committee of B R 
Ambedkar Centre for Biomedical Research, Delhi, India. 
All experimental procedures were carried out in 
accordance with the guidelines of the Committee for the 
Purpose of Control and Supervision of Experiments on 
Animals (CPCSEA), India. 
Sympathectomy was obtained by 6-OHDA 
(100 mg/kg) administered two times over a 1-week 
period. The drug was dissolved in 0.9 % w/v NaCl 
solution containing 1 % ascorbic acid and was injected 
intraperitoneally. The adequacy of sympathectomy was 
verified by the drastic attenuation of the pressor and 
tachycardic responses to tyramine (100 µg/kg, i.v.) 
(Mircoli et al. 2002). 
Control rats were injected vehicle alone. 24 h 
after sympathectomy or vehicle injection, rats received 
daily L-NAME 50 mg/kg dissolved in water or only 
water administered through gavage for 7 days. Thus our 
study had four groups as follows: 
Group I (C): (n=10) Control rats with intact sympathetic 
nerve supply. 
Group II (CL): (n=10) Chronic L-NAME treated control 
rats. 
Group III (S): (n=10) Sympathectomized rats. 
Group IV (SL): (n=10) Chronic L-NAME treated sympa-
thectomized rats. 
 
Surgical preparation of animals 
Rats were anesthetized with urethane 
(1000 mg/kg, i.p.) and placed on a heated surgical table 
so as to maintain body temperature at around 37 °C. 
Tracheostomy was performed and animals were allowed 
to breath spontaneously through tracheal cannula. After 
tracheal cannulation, femoral artery was cannulated and 
arterial blood pressure (ABP) recorded by pressure 
transducer (Statham-P23D). The femoral vein was also 
cannulated for drug administration. Prior to recording 
ABP, pressure recording system was calibrated with the 
help of a mercury manometer. ABP was measured after 
20 min of stabilization period.  
ABP and heart rate (HR) were recorded on a 
Power Lab data-acquisition system (4SP, AD 
Instruments, Australia) with a computerized analysis 
programme (Chart 5.4.2, AD Instruments, Australia).  
 
Measurement of baroreflex sensitivity (BRS) 
BRS was measured by administering 
phenylepherine (20 µg/ml/kg) and sodium nitroprusside 
(20 µg/ml/kg) through venous catheter. Each drug was 
injected i.v. as bolus dose to cause respectively rise and 
fall in ABP. Injections were separated by 15 min interval 
to allow the parameters to stabilize. The relationship 
between rise in systolic blood pressure (SBP) evoked by 
phenylephrine and associated bradycardia or fall in SBP 
evoked by sodium nitroprusside and associated 
tachycardia was assessed by regression analysis for 
individual animal. The regression coefficient (slope of 
regression line) expressed as beats per minute per mm of 
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mercury (bpm/mm Hg), was taken as an index of BRS. 
 
Electrocardiogram (ECG) recording 
Bipolar limb lead II was used for recording 
ECG. Electrodes were placed subcutaneously and were 
connected through a bioamplifier (AD instruments, 
Australia) to the Power Lab data-acquisition system. 
 
Estimation of heart rate variability (HRV) 
We assessed heart rate variability by time 
domain as well as frequency domain (spectral) analysis of 
each of 5-min ECG recording using HRV software (AD 
Instruments, Australia). Parameter used for time domain 
analysis was SDNN i.e. standard deviation of normal R-R 
intervals. It is expressed in milliseconds (ms) and 
provides a measure of the total variability of heart rate. 
The other time domain parameter was square root of the 
mean squared differences of successive R-R intervals 
(RMSSD). RMSSD estimates parasympathetic drive of 
autonomic nervous system. Power spectral analysis of 
heart rate variability was performed by fast-Fourier 
transformation technique. Frequency bands defined for 
spectral analysis were: total spectral power (P) from 0 to 
3 Hz, low frequency (LF) band from 0.25 to 1 Hz and 
high frequency (HF) band from 1 to 3Hz (corresponding 
to the observed respiratory frequency of animals). The 
frequency ranges chosen were based on data from 
previous report (Baumert et al. 2007). Spectral power in 
different frequency bands is expressed in ms2. The LF to 
HF ratio (LF : HF) was calculated to estimate the 
sympatho-vagal balance.  
Chemicals 
Chemicals employed in the experimental 
protocol were L-NAME, 6-hydroxydopamine, 
phenylephrine hydrochloride, sodium nitroprusside, and 
urethane. All chemicals used in this study were of 
analytical grade and were obtained from Sigma-Aldrich 
(USA) and Merck.  
 
Statistical analysis 
The results are presented as means ± S.E.M. 
Statistical significance was calculated from Kruskal- Wallis 
test with post-hoc Dunn’s test. The value was considered 
significant at p<0.05. Statistical analysis was performed 




Effect of L-NAME on hemodynamic responses of control 
and sympathectomized rats 
Table 1 shows cardiovascular data after chronic 
L-NAME treatment of control and sympathectomized 
rats. Baseline blood pressure and heart rate were similar 
in control and sympathectomized rats. After chronic 
L-NAME treatment of control rats a significant rise in 
blood pressure and heart rate was observed but in 
sympathectomized rats the pressor and tachycardic effect 
of L-NAME was not seen. As a result, a significant 
difference in heart rate and blood pressure was observed 
in L-NAME treated sympathectomized rats in 
comparison to L-NAME treated control ones. 
 
 
Table 1. Chronic L-NAME induced hemodynamic responses in control and sympathectomized rats. 
 
Parameter Control (n=10) CL (n=10) S (n=10) SL (n=10) 
SBP (mm Hg) 112.4 ± 1.2 174.3 ± 5.5* 106.1 ± 1.7† 116.6 ± 1.7† 
DBP (mm Hg) 64.9 ± 2.9 117.9 ± 4.7* 59.4 ± 2.2† 68.5 ± 1.6† 
MAP (mm Hg) 81.5 ± 1.6 136.7 ± 4.9* 71.8 ± 3.2† 85.0 ± 1.6† 
HR (bpm) 315.2 ± 11.4 371.2 ± 8.0* 357.7 ± 9.3 310 ± 7.1†‡ 
 
Control, rats with intact sympathetic nervous system; S, sympathectomized rats; CL, control rats treated with chronic L-NAME; 
SL, sympathectomized rats treated with chronic L-NAME; SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean 
arterial pressure; HR, heart rate; n, number of animals; bpm, beats per minute. Values are means ± S.E.M. * p<0.05 versus control; 
† p<0.05 versus CL; ‡ p<0.05 versus S 
 
 
Baroreflex responses following L-NAME in control and 
sympathectomized rats 
BRS for bradycardia reflex (Fig. 1A) consequent 
to rise in pressure by phenylepherine was similar in 
control and sympathectomized rats (2.0±0.2 bpm/mm Hg 
versus 2.0±0.1 bpm/mm Hg, ns). Chronic L-NAME 
treatment attenuated BRS for bradycardia reflex in 
control rats (0.8±0.04 bpm/mm Hg versus 2.0±0.2 
bpm/mm Hg, p<0.05) but not in sympathectomized rats 
(1.7±0.1 bpm/mm Hg versus 2.0±0.1 bpm/mm Hg, ns). 
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Therefore, L-NAME associated diminished BRS for 
bradycardia reflex was normalized after sympathectomy 
(Fig. 1A). 
Baseline BRS for tachycardia reflex (Fig. 1B) 
was lower in sympathectomized rats compared to control 
animals (0.7±0.1 bpm/mm Hg versus 1.4± 
0.09 bpm/mm Hg, p<0.05). A marked suppression of 
BRS was seen after 7 days of L-NAME administration in 
control animals (0.7±0.05 bpm/mm Hg versus 1.4± 
0.09 bpm/mm Hg, p<0.05). BRS for tachycardia response 
remained low after L-NAME administration in 
sympathectomized rats (0.9±0.06 bpm/mm Hg versus 
0.7±0.1 bpm/mm Hg, ns).  
 
Effect of L-NAME on HRV of control and 
sympathectomized rats 
Figure 2 demonstrates time domain parameters 
of HRV. Baseline SDNN (Fig. 2A) was similar in control 
and sympathectomized rats (4.1±0.2 ms versus 3.6± 
0.2 ms, ns). A significant fall of SDNN was seen 
following L-NAME treatment in control (2.2±0.1 ms 
versus 4.1±0.2 ms, p<0.05) but not in sympathectomized 
rats (3.9±0.2 ms versus 3.6±0.2 ms, ns).  
RMSSD (Fig. 2B) showed similar trend with no 
difference between control and sympathectomized rats 
(4.3±0.2 ms versus 3.9±0.1 ms, ns). L-NAME 
administration in control rats significantly lowered 
RMSSD values (1.7±0.1 ms versus 4.3±0.2 ms, p<0.05) 
but this fall was not seen after L-NAME administration 
in sympathectomized animals (3.6±0.2 ms versus 
3.9±0.1 ms, ns). RMSSD was also significantly lower in 
L-NAME treated control rats compared to L-NAME 
treated sympathectomized rats (1.7±0.1 ms versus 









Fig. 1. Baroreflex sensitivity (BRS) 
measured as ratio of (A) bradycardia 
response to rise in pressure by 
phenylephrine or (B) tachycardia 
response to fall in pressure by sodium 
nitroprusside in each study group. 
C, Control, rats with intact 
sympathetic nervous system; CL, 
control rats treated with chronic 
L-NAME; S, sympathectomized rats; 
SL, sympathectomized rats treated 
with chronic L-NAME. Values are 
means ± S.E.M. (n=10). * p<0.05 





Fig. 2. Bar graphs depicting (A) 
Standard deviation of normal R-R 
intervals (SDNN) and (B) Root mean 
squared difference of successive R-R 
intervals (RMSSD) in different groups. 
C, control, rats with intact sympathetic 
nervous system; CL, control rats 
treated with chronic L-NAME; S, 
sympathectomized rats; SL, 
sympathectomized rats treated with 
chronic L-NAME. Values are means ± 
S.E.M. (n=10). * p<0.05 versus 
Control; † p<0.05 versus CL 
 
 
Figure 3 is original tracing of record showing 
power spectral density of HRV with or without L-NAME 
in control and sympathectomized animals. Baseline total 
spectral power of HRV (Fig. 4A) did not vary between 
control and sympathectomized rats (10.1±0.9 ms2 versus 
9.6±0.9 ms2, ns). L-NAME treatment in control rats 
produced a significant fall in total power (2.7±0.3 ms2 
versus 10.1±0.9 ms2, p<0.05). However no difference was 
seen after L-NAME in sympathectomized rats (9.4±0.6 
ms2 versus 9.6±0.9 ms2, ns). Comparison of total power 
after L-NAME in control and sympathectomized rats 
showed a significant difference (p<0.05). 
Low frequency spectral power of HRV (Fig. 
4B) showed no variation between control and 
sympathectomized rats (1.1±0.1 ms2 versus 0.9±0.1 ms2, 
ns). Reduced LF spectral power was observed after 
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L-NAME in control rats (0.4±0.04 ms2 versus 1.1±0.1 
ms2, p<0.05) but no such difference was observed in 









Fig. 3. Power Spectral density of 
heart rate with or without L-NAME in 
control and sympathectomized rats. 
(A) control rats, (B) control rats 
treated with chronic L-NAME, 
(C) sympathectomized rats and (D) 











Fig. 4. (A) Total spectral power, 
(B) low frequency spectral power, 
(C) high frequency spectral power and 
(D) LF to HF ratio (LF/HF) in each 
study group. C, Control, rats with 
intact sympathetic nervous system; 
CL, control rats treated with chronic 
L-NAME; S, sympathectomized rats; 
SL, sympathectomized rats treated 
with chronic L-NAME; LF, low 
frequency; HF, high frequency. Values 
are means ± S.E.M. (n=10). * p<0.05 








HF spectral power (Fig. 4C) of control rats was 
similar to sympathectomized animals (5.6±0.7 ms2 versus 
4.5±0.3 ms2, ns). HF spectral power decreased 
significantly following L-NAME in control rats (1.0±0.1 
ms2 versus 5.6±0.7 ms2, p<0.05) but no change in HF 
spectral power resulted after chronic administration of 
L-NAME in sympathectomized rats (4.0±0.3 ms2 versus 
4.5±0.3 ms2, ns). HF power was significantly low after 
L-NAME in control rats compared to that in 
sympathectomized rats (p<0.05). LF to HF ratio (Fig. 4D) 
did not differ between control and sympathectomized rats 
(ns). LF to HF ratio increased significantly following 
chronic L-NAME treatment in control rats (0.4±0.05 
versus 0.2±0.01, p<0.05) but no change was observed 
after L-NAME treatment of sympathectomized rats 
(0.2±0.01 versus 0.2±0.04, ns).  





Nitric oxide is said to buffer cardiac autonomic 
balance by restraining sympathetic and facilitating 
parasympathetic outflow (Schultz 2009). Deficiency of 
NO in addition to elevating blood pressure is thought to 
produce a dysfunctional state of autonomic balance with 
sympathetic activation. Although concept of 
sympathoexcitation in NO deficiency induced 
hypertension has been reported by previous studies but 
contradictory results make it difficult for a firm 
conclusion to be drawn (Biancardi et al. 2007, Young et 
al. 2009, Chaswal et al. 2011, dos Santos et al. 2010, 
Ramchandra et al. 2007). Our study using chemical 
sympathectomy by 6-OHDA provides an indirect 
evidence of a state of sympathetic activation and its 
antagonistic influence in chronic L-NAME induced 
hypertension. The study shows that long term L-NAME 
treatment in control rats with intact sympathetic 
innervation resulted in a marked rise of blood pressure 
accompanied by tachycardia, attenuation of BRS for both 
bradycardia as well as tachycardia response, besides a 
significant decline in time and frequency domain 
parameters of HRV. Furthermore, sympathectomy by 
6-OHDA reversed not only the cardiac autonomic 
dysfunction but also the hypertensive effect of L-NAME. 
The present study was conducted on urethane 
anesthetized rats. Though in case of anesthetized 
preparation there may be interference of autonomic 
functions. However, in our study urethane has proved to 
be better than other anesthetics. Urethane is characterized 
by fairly good preservation of cardiovascular reflex 
responses and it minimally interferes with the 
physiological relevance of data collected in the 
anesthetized animals (Maggi and Meli 1986). 
Demonstration of pressor response following 
chronic administration of L-NAME is an expected 
finding and is in agreement with earlier reports 
(Biancardi et al. 2007, Scrogin et al. 1998). However, the 
precise mechanism of L-NAME induced pressure rise 
remains ill defined. Our study showed that chemical 
sympathectomy by 6-OHDA completely reversed the 
pressure rise seen after chronic L-NAME treatment, thus 
suggesting the existence of an important influence of 
sympathetic nervous system in mediating vascular effects 
of L-NAME. Our results are in agreement to a study by 
Sander et al. (1997) who found more than 50 % 
attenuation of hypertensive response to 6 days of 
continuous L-NAME (50 mg/kg/day) administration by 
guanethidine induced sympathectomy. However, on 
literature survey we came across studies which contradict 
our findings as the one by Lepori et al. (1999) who 
reported potentiation of vasoconstrictor effect of NO 
synthesis inhibition by sympathectomy. This study was 
conducted on humans who had undergone thoracic 
sympathectomy for hyperhydrosis and an infusion of 
L-NMMA was used for blocking NO synthesis. The 
difference in species and methodology may explain 
divergent results.  
Baroreceptor dysfunction may also contribute to 
pressor response of L-NAME. In our study presence of 
tachycardia despite elevation of blood pressure by 
L-NAME points to impairment of baroreceptor function, 
which was evident by attenuation of BRS for both 
bradycardia and tachycardia response in L-NAME treated 
rats. As impaired BRS for bradycardia response was 
normalized after sympathectomy, it reflects an important 
role of sympathetic activation rather than the structural 
alteration of vessels in decreasing BRS following 
L-NAME treatment. In agreement to our finding, 
sympathetic activation mediated baroreceptor impairment 
has also been reported by an earlier study (Ferrari et al. 
1991). Though the reason for negative effect of 
sympathetic nervous system on baroreceptor-heart rate 
reflex is not investigated by our study but we may 
speculate that sympathetic over activity may be 
associated with increased tone of vessels such as carotid 
artery, reducing arterial distensibility and thus afferent 
discharge of baroreceptors (Lacolley et al. 1995, 
Mangoni et al. 1997). On removal of sympathetic 
influence, the arterial tone gets normalized and thus BRS 
is restored. However sympathectomy in our study 
normalized only BRS for bradycardia response and we 
found decreased rather than preserved BRS for 
tachycardia response in L-NAME treated 
sympathectomized rats. This finding may reflect not only 
reduced sympathetic stimulation but also decreased 
parasympathetic withdrawal in chronic L-NAME treated 
sympathectomized rats. 
In addition to impaired BRS, L-NAME treated 
hypertensive rats of our study also showed decrement of 
time and frequency domain parameters of HRV along 
with a significant rise of LF to HF ratio. Fall of RMSSD 
and HF spectral power of HRV, both of which are 
measures of parasympathetic tone and resting tachycardia 
suggest depression of cardiac vagal tone and 
predominance of sympathetic tone in L-NAME treated 
rats. As expected, reduction of cardiac vagal control was 
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associated with a fall in SDNN, a measure of total 
variability along with reduced total spectral power. 
Another interesting finding was a reduction in LF spectral 
power following L-NAME treatment. Our results of HRV 
are in agreement to an earlier study by Souza et al. (2001) 
who also showed a fall in SDNN and LF spectral power 
in chronic L-NAME treated rats. Observation of 
decreased LF power in presence of sympathetic over 
activity is quite paradoxical, but as LF spectral power of 
HRV represents baroreflex related heart rate fluctuation 
therefore impaired BRS seen in L-NAME treated rats is 
likely to be associated with a reduced LF power (van de 
Borne et al. 1997). Normalization of SDNN, RMSSD, 
total spectral power and also of HF spectral power after 
sympathetic blockade in L-NAME treated rats of our 
study further strengthens the concept of sympathetic over 
activity mediated autonomic alterations in L-NAME 
treated animals. 
Even though our results of sympathectomy 
provide only an indirect indication of state of 
sympathoexcitation in chronic L-NAME treated animals, 
but there is evidence that L-NAME when administered 
orally crosses blood brain barrier and causes inhibition of 
neuronal NOS, increasing central sympathetic outflow 
(Eshima et al. 2000). As explained earlier the enhanced 
sympathetic outflow impairs baroreceptor activity which 
in turn further potentiates the sympathoexcitatory 
response to NO inhibition. 
In conclusion, our findings support the concept 
of increased sympathetic tone as an important pathogenic 
factor contributing to pressor response, impaired 
baroreflex sensitivity and reduced heart rate variability in 
L-NAME induced hypertension. 
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